All News
Filter News
Found 331 articles
-
Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials
1/11/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials.
-
Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.
-
University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate
1/7/2021
Monica McArthur, MD, PhDResearchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world.
-
The U.S. FDA came out to warn health care personnel not to make any changes to the dosing of the vaccines and that doing so would place the public health at risk and undermine “the historic vaccination effort to protect the population.”
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
-
Leading Healthcare Services Organizations Collaborate to Provide Innovative COVID Therapy Access Model
1/5/2021
On December 8, 2020, the National Home Infusion Association announced it had launched a pilot program with Operation Warp Speed and the department of Health and Human Services to expand access to Bamlanivimab for COVID-19-positive eligible patients residing in long-term care facilities.
-
UMSOM's Kathleen Neuzil Receives Marylander of the Year Award For Unprecedented Leadership On COVID-19 Vaccines Research
1/5/2021
Dr. Neuzil Continues Legacy and Global Impact of UMSOM's Center for Vaccine Development & Global Health.
-
Ride Health and ACTIV-2 Partner to Provide Transportation for Nationwide COVID-19 Therapeutic Study
1/5/2021
NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines study leveraging company's COVID-19 equipped transportation network across dozens of sites nationwide
-
Biggest Novel Drug Approvals in 2020
1/4/2021
Here’s a look at the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years. -
As Operation Warp Speed struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.
-
The U.K authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.
-
Operation Warp Speed succeeded on the development component but is failing in the early stages of distribution. Here's everything you need to know about it.
-
The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.
-
U.S. Renal Care to Administer IV Monoclonal Antibody Therapy in Dialysis Clinics to Confirmed COVID-19 Patients
12/29/2020
U.S. Renal Care (USRC), a leading provider of dialysis services caring for more than 26,000 individuals living with kidney disease, announced it will obtain and distribute the monoclonal antibody therapy, Bamlan
-
The vaccine will be able to be administered without needles and in one dose. It also won’t require refrigeration.
-
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
12/28/2020
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate.
-
Yesterday it was reported that the two companies were working to make more of their vaccine than the 1.3 billion it promised to manufacture in 2021.
-
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19
12/23/2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into an agreement with the United States Government to support the development, manufacture and initial distribution of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the acquisition of OncoImmune,
-
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
12/23/2020
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 Vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.